Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytic Sarcoma | 1 | 2025 | 5 | 0.920 |
Why?
|
| Malacoplakia | 1 | 2025 | 4 | 0.900 |
Why?
|
| Genital Diseases, Male | 1 | 2025 | 13 | 0.900 |
Why?
|
| Scrotum | 1 | 2025 | 30 | 0.890 |
Why?
|
| Cell Transdifferentiation | 1 | 2025 | 58 | 0.870 |
Why?
|
| Tryptases | 2 | 2021 | 17 | 0.820 |
Why?
|
| Mast Cells | 2 | 2021 | 65 | 0.790 |
Why?
|
| Multiple Myeloma | 1 | 2025 | 190 | 0.770 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2021 | 212 | 0.760 |
Why?
|
| Mastocytosis, Systemic | 1 | 2020 | 8 | 0.650 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 9 | 0.640 |
Why?
|
| Lung Transplantation | 1 | 2025 | 357 | 0.640 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 468 | 0.530 |
Why?
|
| Diet Therapy | 1 | 2017 | 41 | 0.510 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.510 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2017 | 77 | 0.490 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 338 | 0.440 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 304 | 0.440 |
Why?
|
| Biomarkers | 1 | 2020 | 3429 | 0.320 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 1916 | 0.260 |
Why?
|
| Paget Disease, Extramammary | 1 | 2025 | 5 | 0.240 |
Why?
|
| Vulvar Neoplasms | 1 | 2025 | 21 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2025 | 62 | 0.230 |
Why?
|
| Anaphylaxis | 2 | 2023 | 91 | 0.220 |
Why?
|
| ras Proteins | 1 | 2025 | 147 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 174 | 0.220 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 433 | 0.210 |
Why?
|
| Arthropod Venoms | 1 | 2023 | 7 | 0.200 |
Why?
|
| Ants | 1 | 2023 | 8 | 0.200 |
Why?
|
| Lymph Nodes | 1 | 2025 | 364 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 246 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2025 | 666 | 0.200 |
Why?
|
| Insect Bites and Stings | 1 | 2023 | 39 | 0.200 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2025 | 147 | 0.200 |
Why?
|
| Immunocompromised Host | 1 | 2025 | 313 | 0.190 |
Why?
|
| Mutation | 2 | 2025 | 6207 | 0.180 |
Why?
|
| Urticaria | 1 | 2021 | 20 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 454 | 0.170 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 125 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2025 | 1617 | 0.140 |
Why?
|
| Humans | 11 | 2025 | 132194 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2017 | 132 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 73 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6935 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 309 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 13356 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2023 | 15103 | 0.110 |
Why?
|
| Female | 6 | 2025 | 71459 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1261 | 0.100 |
Why?
|
| Male | 5 | 2025 | 65494 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1307 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2658 | 0.100 |
Why?
|
| Logistic Models | 1 | 2017 | 1841 | 0.090 |
Why?
|
| Adolescent | 3 | 2021 | 21021 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4965 | 0.080 |
Why?
|
| Phenotype | 1 | 2020 | 4550 | 0.080 |
Why?
|
| Middle Aged | 2 | 2025 | 28963 | 0.070 |
Why?
|
| Child | 2 | 2020 | 26383 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5284 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1624 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2025 | 9 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2025 | 107 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2025 | 160 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 133 | 0.050 |
Why?
|
| Aged | 3 | 2025 | 21304 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 10131 | 0.050 |
Why?
|
| Cetirizine | 1 | 2021 | 4 | 0.040 |
Why?
|
| Mastocytosis | 1 | 2021 | 7 | 0.040 |
Why?
|
| Anti-Allergic Agents | 1 | 2021 | 29 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13022 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2021 | 125 | 0.040 |
Why?
|
| Environment | 1 | 2021 | 149 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 222 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 140 | 0.040 |
Why?
|
| Malnutrition | 1 | 2021 | 156 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2017 | 17772 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 395 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3439 | 0.020 |
Why?
|
| HIV Infections | 1 | 2021 | 2044 | 0.020 |
Why?
|
| Neoplasms | 1 | 2021 | 2968 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 31771 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 34291 | 0.010 |
Why?
|